1
|
Emery JD, Shaw K, Williams B, et al: The
role of primary care in early detection and follow-up of cancer.
Nat Rev Clin Oncol. 11:38–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hutchinson L: Genetics: tracking clonal
origin of prostate cancer. Nat Rev Clin Oncol. 11:42014. View Article : Google Scholar
|
3
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011.PubMed/NCBI
|
5
|
Sun K and Lai EC: Adult-specific functions
of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lewis H, Lance R, Troyer D, et al: miR-888
is an expressed prostatic secretions-derived microRNA that promotes
prostate cell growth and migration. Cell Cycle. 13:227–239. 2014.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Ji J, Yamashita T, Budhu A, et al:
Identification of microRNA-181 by genome-wide screening as a
critical player in EpCAM-positive hepatic cancer stem cells.
Hepatology. 50:472–480. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wang B, Hsu SH, Majumder S, et al:
TGFbeta-mediated upregulation of hepatic miR-181b promotes
hepatocarcinogenesis by targeting TIMP3. Oncogene. 29:1787–1797.
2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lin S, Pan L, Guo S, et al: Prognostic
role of microRNA-181a/b in hematological malignancies: a
meta-analysis. PLoS One. 8:e595322013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Holter E, Kotaja N, Mäkela S, et al:
Inhibition of androgen receptor (AR) function by the reproductive
orphan nuclear receptor DAX-1. Mol Endocrinol. 16:515–528. 2002.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Hessels D and Schalken JA: Urinary
biomarkers for prostate cancer: a review. Asian J Androl.
15:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Sita-Lumsden A, Dart DA, Waxman J and
Bevan CL: Circulating microRNAs as potential new biomarkers for
prostate cancer. Br J Cancer. 108:1925–1930. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kim WT and Kim WJ: MicroRNAs in prostate
cancer. Prostate Int. 1:3–9. 2013. View Article : Google Scholar
|
14
|
McCabe ER: DAX1: Increasing complexity in
the roles of this novel nuclear receptor. Mol Cell Endocrinol.
265–266:179–182. 2007.PubMed/NCBI
|
15
|
El-Khairi R, Martinez-Aguayo A,
Ferraz-de-Souza B, Lin L and Achermann JC: Role of DAX-1 (NR0B1)
and steroidogenic factor-1 (NR5A1) in human adrenal function.
Endocr Dev. 20:38–46. 2011.PubMed/NCBI
|
16
|
Li J, Lu Y, Liu R, et al: DAX1 suppresses
FXR transactivity as a novel co-repressor. Biochem Biophys Res
Commun. 412:660–666. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Jadhav U, Harris RM and Jameson JL:
Hypogonadotropic hypogonadism in subjects with DAX1 mutations. Mol
Cell Endocrinol. 346:65–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chae BJ, Lee A, Bae JS, Song BJ and Jung
SS: Expression of nuclear receptor DAX-1 and androgen receptor in
human breast cancer. J Surg Oncol. 103:768–772. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lanzino M, Maris P, Sirianni R, et al:
DAX-1, as an androgen-target gene, inhibits aromatase expression: a
novel mechanism blocking estrogen-dependent breast cancer cell
proliferation. Cell Death Dis. 4:e7242013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Lalli E and Alonso J: Targeting DAX-1 in
embryonic stem cells and cancer. Expert Opin Ther Targets.
14:169–177. 2010. View Article : Google Scholar : PubMed/NCBI
|